Literature DB >> 29151451

Fracture risk assessment tool (FRAX) and for the diagnosis of osteoporosis in Japanese middle-aged and elderly women: Chiba bone survey.

Rena Oka1,2, Masahiro Ohira2, Sawako Suzuki3, Tomohiko Yoshida4, Hisashi Koide3, Tomoaki Tanaka3, Ichiro Tatsuno2.   

Abstract

Osteoporosis not only increases bone fracture risk but also affects survival in postmenopausal women. Although osteoporosis is diagnosed based on low bone mineral density (BMD) determined by dual energy X-ray absorptiometry (DXA), BMD measurement is sometimes difficult because DXA is not widely available in the community. The Fracture Risk Assessment tool (FRAX) can predict 10-year major osteoporotic fracture risk and hip fracture risk with or without femoral neck BMD. The FRAX has not been investigated adequately in community-dwelling Japanese women. We administered the FRAX tool in 13,421 Japanese women who underwent DXA-based forearm BMD measurement in Chiba Bone Survey, a population-based, multicenter, cross-sectional study of postmenopausal osteoporosis conducted in Chiba, Japan. Mean age was 57.77 ± 9.24 years. Mean forearm BMD was 87.94 ± 17.00% of young adult mean (YAM). Mean FRAX major osteoporotic fracture risk without femoral neck BMD was 7.06 ± 5.22%. BMD decreased and percentage of osteoporosis increased from age 55 onward. Age distribution of percentage of subjects with FRAX major osteoporotic fracture risk >15% was similar to that of percentage of osteoporosis subjects. We identified the cutoff value of FRAX major osteoporotic fracture risk for diagnosis of osteoporosis as 7.2%. With this cutoff, the positive likelihood ratio was over 1.0 at age 55 and above but accuracy was low. In conclusion, FRAX without femoral neck BMD reflects bone status, and may be useful to diagnose osteoporosis in Japanese women aged 55 and above, although the sensitivity was low for osteoporosis screening, especially in middle-aged women.

Entities:  

Keywords:  Bone mineral density; Fracture risk assessment tool; Hip fracture risk; Major osteoporotic fracture risk; Osteoporosis

Mesh:

Year:  2017        PMID: 29151451     DOI: 10.1507/endocrj.EJ17-0331

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  6 in total

1.  Diagnostic and Gradation Model of Osteoporosis Based on Improved Deep U-Net Network.

Authors:  Jian Liu; Jian Wang; Weiwei Ruan; Chengshan Lin; Daguo Chen
Journal:  J Med Syst       Date:  2019-12-07       Impact factor: 4.460

2.  Comparison between real-world practice and application of the FRAX algorithm in the treatment of osteoporosis.

Authors:  Francesca Zoccarato; Chiara Ceolin; Caterina Trevisan; Anna Citron; Labjona Haxhiaj; Aurelio Guarnaccia; Matteo Panozzo; Carlotta Campodall'Orto; Alessandra Coin; Sandro Giannini; Giuseppe Sergi
Journal:  Aging Clin Exp Res       Date:  2022-08-16       Impact factor: 4.481

Review 3.  Clinical guidelines for the application of panoramic radiographs in screening for osteoporosis.

Authors:  Akira Taguchi; Ray Tanaka; Naoya Kakimoto; Yasuhiro Morimoto; Yoshinori Arai; Takafumi Hayashi; Tohru Kurabayashi; Akitoshi Katsumata; Junichi Asaumi
Journal:  Oral Radiol       Date:  2021-02-23       Impact factor: 1.852

4.  Systemic immune-inflammation index acts as a novel diagnostic biomarker for postmenopausal osteoporosis and could predict the risk of osteoporotic fracture.

Authors:  Hong Fang; Hanqing Zhang; Zhi Wang; Zhongming Zhou; Yunjun Li; Lin Lu
Journal:  J Clin Lab Anal       Date:  2019-08-19       Impact factor: 2.352

5.  Health-promoting lifestyle and quality of life in affected and unaffected menopausal women by primary osteoporosis.

Authors:  Somayeh Abdolalipour; Mojgan Mirghafourvand; Nafiseh Ghassab-Abdollahi; Azizeh Farshbaf-Khalili
Journal:  J Educ Health Promot       Date:  2021-02-27

6.  Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis.

Authors:  Filippo Migliorini; Giorgia Colarossi; Jörg Eschweiler; Francesco Oliva; Arne Driessen; Nicola Maffulli
Journal:  Br Med Bull       Date:  2022-09-22       Impact factor: 5.841

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.